iBio tests long-acting obesity antibody designed to preserve muscle
iBio (NASDAQ: IBIO) has announced it has dosed the first participant in its Phase 1 clinical trial for IBIO-600, a long-acting anti-myostatin/GDF11 monoclonal antibody aimed at preserving muscle and improving body composition in adults with overweight and obesity. This milestone marks iBio's transition to a clinical-stage company. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with results expected in the second half of 2027.
https://www.stocktitan.net/news/IBIO/i-bio-becomes-a-clinical-stage-company-with-first-participant-dosed-nex9njjebp2z.html